Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial
Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial have?
Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial has 135 citations in the OpenAlex counts ScholarIQ stores.
When was Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial published?
Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial has 2018 year in the ScholarIQ index.
What is the open-access status of Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial?
Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial has hybrid oa status in the ScholarIQ index.
What is the DOI of Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial?
The DOI for Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial is on the source record.
What is the PMID of Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial?
The PMID for Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial is on the source record.
What is the OpenAlex record for Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial?
The OpenAlex for Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial is on the source record.